INVOKANA ® (canagliflozin) Demonstrated Significant Renal Protective Benefits in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Canagliflozin | Chronic Kidney Disease | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Invokana | Pharmaceuticals | Urology & Nephrology